Search

everythinglearnresearchcommunity

for

Search:↓

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

CTP-543 is generally safe for treating alopecia areata.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

Baricitinib is an effective treatment for severe alopecia areata.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.